Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Rectal Malignant Neoplasms 1Radiation Injuries 1Postoperative Complications 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Head and Neck Neoplasms 1HPV-Related Squamous Cell Carcinoma 1Fatigue 1Carcinoma 1

Interventions

pembrolizumab 32Cisplatin 23Cetuximab 14Carboplatin 13Magnetic Resonance Spectroscopy 12Specimen Handling 10Radiotherapy, Intensity-Modulated 10Paclitaxel 9Nivolumab 9Docetaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Radiotherapy 5Biopsy 5dostarlimab 4atezolizumab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Taxes 3Radiation 3Fulvestrant 3Fluorouracil 3budigalimab 2amivantamab 2abemaciclib 2Radiotherapy, Image-Guided 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Chemoradiotherapy × 30 days × Clear all
NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
182 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡